The Claim
In men with hypogonadotropic hypogonadism, gonadotropin therapy increases the density of seminiferous tubules greater than 300 μm in diameter on ultrasound, and this density is more strongly correlated with sperm count than testicular volume.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In men with hypogonadotropic hypogonadism, gonadotropin therapy increases the density of large seminiferous tubules visible on ultrasound, and this increase correlates more closely with sperm count than the overall size of the testicles.
See the scientific wording
In men with hypogonadotropic hypogonadism, the density of seminiferous tubules greater than 300 μm in diameter on ultrasound increases during gonadotropin therapy and is more strongly correlated with sperm count than testicular volume, suggesting tubule morphology may be a more sensitive marker of spermatogenic activity than overall testis size.
Hormone therapy stimulates the testicles to produce more testosterone and other signals that activate sperm-producing cells inside tiny tubes. As these cells multiply and mature, they fill the tubes, making them thicker and more numerous. These thickened tubes show up clearly on ultrasound and match better with how many sperm are made than the overall size of the testicle.
What the research says
1 studyIn men with a hormone problem causing no sperm, doctors found that thicker tubes inside the testicles (seen on ultrasound) showed up right before sperm started appearing, and more thick tubes meant more sperm — better than just measuring how big the whole testicle is.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.